LOGOLOGOLOGOLOGO
  • About us
    • What we do
    • Who we are
      • Governance
      • Staff
      • Vacancies
  • Members
    • EuropaBio Members
    • About Membership
  • How we work
    • Healthcare Biotechnology Council
      • Patient BioForum
      • Study – Impact of the EU’s General Pharmaceutical Legislation
    • Industrial Biotechnology Council
      • EFIB
      • Microorganisms
    • National Associations Council
    • SME Platform
    • Biomanufacturing Platform
      • Biotechnology in our Lives
  • Activities
    • 25 Years of Innovation
    • The EU Biotech Act
    • European Biotech Week
    • EU Projects
      • PRIMED Project
      • APROVALS Project
  • News & Events
    • News
    • Events
  • Library
Become a member
✕

Open Letter of Business and Agri-Food Industry stakeholders on the need for a high-performing EFSA to boost the competitiveness of the EU agri-food sector

30/05/2025

OPEN LETTER

Brussels, 28 May 2025

The European Commission’s Vision for Agriculture and Food recognises the essential role of the agrifood sector for the EU’s competitiveness. This critical sector employs over 30 million people and substantially contributes to the EU’s economy (EUR 900 billion in 2022)(1). Nevertheless, business and food and feed industry operators face significant regulatory challenges in the EU which put them at a competitive disadvantage to other regions.

The undersigned organisations represent thousands of food and feed business operators along the agri-food chain; including food and feed primary, secondary producers, and ingredients suppliers that are directly and indirectly subject to the scientific outputs, guidance documents and opinions of the European Food Safety Authority (EFSA). We support the Commission’s ambition of regulatory simplification and streamlining. This is essential to accelerate access to innovation and reinforce the EU’s global competitiveness. We consider the ongoing EFSA’s Performance Evaluation2 as a unique opportunity to make the Commission ambitions a reality.

Ensuring the safety of the agri-food products is a priority for our industries. It is also a core principle of Regulation (EC) No 178/2002 (General Food Law), which established EFSA as an independent agency to provide scientific advice and support, thereby ensuring a high level of consumer protection. The outputs of EFSA are of great importance to our industries, and we value the work performed by EFSA. In recent years, we have noted several promising developments, particularly in relation to stakeholder engagement and development of EFSA's Catalogue of support initiatives.

While we acknowledge certain improvements, we are concerned about ongoing challenges with EFSA’s performance and timeliness which increasingly discourages many businesses from entering the EU market. Efficient and operational risk assessment processes are crucial to support the uptake of innovation and the acceleration to more resilient and sustainable food and feed production.

This open letter underlines the main horizontal challenges faced by industry stakeholders at the risk assessment level and proposes solutions for more efficient and science-based processes. Ensuring the continued development of innovative agri-food products necessitating a safety assessment for authorisation within the EU requires urgent action. We therefore call on the Commission and EFSA to speed up the delivery of EFSA’s performance evaluation and to give full consideration to the challenges highlighted in this letter.

 

Download and read the full open letter below

 

(1) Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions: A Vision for Agriculture and Food; Shaping together an attractive farming and agri-food sector for future generations (link)

Open Letter of Business and Agri-Food Industry stakeholders on the need for a high-performing EFSA to boost the competitiveness of the EU agri-food sector


Download
Share
Francesca Degli Agostini
Francesca Degli Agostini

Related posts

10/06/2025

EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union


Read more
10/06/2025

The EU economic and scientific future starts with the EU Biotech Act


Read more
05/06/2025

The GPL must include biotech & life science to unleash EU innovation


Read more

Important links

  • EuropaBio Position on the EU Biotech Act: Prosperity, resilience and leadership for the European Union
  • The EU economic and scientific future starts with the EU Biotech Act

Categories in our Newsroom

EBIO-white

EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

Contact us

Extra links

Members
Staff
Privacy policy
Legal & cookies
Events
Newsroom

Become a member

Media pack

© 2025 Europabio. All Rights Reserved. Designed by EYAS
Become a member

Algal Omega 3

Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

Cheese

Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.

Clothes

Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

Vitamin B2

The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

Detergents

Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

Insulin

Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.